Paragraph 22
Where the applicant, in relation to all or any particular therapeutic indications, omits any information by virtue of paragraph 5 of Schedule 2—
(a)
detailed proposals for the programme of studies referred to in that paragraph (including a proposed period for carrying them out) for the purposes of a reassessment of the benefit/risk profile in relation to those indications; and
(b)
a statement as to any proposal that the product in question should be administered for those indications only under strict medical supervision, possibly in a hospital, and, for a radiopharmaceutical to which Directive 89/343/EEC applies, by an authorized person.